Pharmacy giant CVS Health has agreed to buy Aetna in a $69 billion blockbuster acquisition that could rein in healthcare costs and transform its 9,700 pharmacy storefronts into community medical hubs for primary care and basic procedures, people familiar with the deal said Sunday.
The pharmacy chain agreed to buy Aetna for about $207 per share, broken down into $145 in cash and the rest in stock, according to those sources. The deal is expected to close in the second half of 2018, subject to approval by shareholders and regulators.
If approved, the mega-merger would create a giant healthcare company, allowing CVS to provide a broad range of health services to Aetna’s 22 million medical members at its nationwide network of pharmacies and walk-in clinics, and further decrease the drug store titan's reliance on the retail sales that have faced increasing competition.
And the deal is likely to set off even more mergers in the health-care industry, which has been undergoing consolidation and faces potential new competition from Amazon. It will also position Aetna to be more competitive with UnitedHealth Group, an insurer that has already strayed outside the typical boundaries, with a large and growing business in pharmacy care services, clinics and surgery care centers and healthcare data.
"I think it will create more consolidation among the insurers and retailers, blurring the lines," said Ana Gupte, an analyst at Leerink Partners, who recently pointed to retail giants Walgreens Boots Alliance or Walmart as potential "dark horse acquirers" of the health insurer Humana.
Wall Street analysts have said that the deal could lower health spending -- if, for example, CVS can push customers to use a walk-in clinics instead of an emergency room for minor problems. But consumer advocates argue the deal would limit consumer choice and could make it even harder for new companies to enter into a market increasingly dominated by behemoth companies.
Even before the announcement, the familiar drug store chain has been a dominant player in the big business of negotiating drug prices for insurers and employees. CVS made its presence strongly felt in Florida around 2004, when it finalized the deal to purchase 1,260 Eckerd stores in the southern United States from J.C. Penney Corp; 620 of those stores were in Florida. The new merger would give CVS an even broader role in managing healthcare.
The combined company could leverage massive amounts of data from both Aetna's medical claims and CVS's vast number of touchpoints to consumers, including its 9,700 retail stores and 1,100 MinuteClinics.
CVS plans to turn those locations into a kind of community health hub, where pharmacists and nurses can provide follow-up and monitoring to patients recently released from hospital -- reviewing and managing their medications and helping them to stay out of the hospital. (Hospital readmissions are seen as an avoidable cost in healthcare).
The storefronts could also transform preventative care, offering wellness, nutrition and even imaging services -- saving costs by keeping people healthier and providing care in a lower-cost setting than a hospital.
Pharmacists and nurses could help make sure patients with chronic diseases stay on their meds and provide counseling between doctor's visits, which would keep those conditions in control.
"Every health insurance company wants to get closer to the consumer," said Dan Mendelson, president of Avalere Health, a consulting firm. "If a patient is better off by getting a home health visit to have someone go through their medications to take them off 10 and eliminate those medications, I want that to happen -- as opposed to someone just filling prescriptions."
The merger would also better insulate CVS and Aetna against looming competition on two fronts.
The mere possibility that Amazon will soon begin selling drugs has shaken the stocks of companies up and down the drug supply chain, from wholesalers to pharmacies. The deal would expand CVS’s business beyond the business of selling drugs and negotiating drug prices, to managing all aspects of a patient’s entire health care -- and could shift its storefronts to become medical hubs, rather than aisles stocked with consumer goods that people can easily buy in other stores or online.
The deal would also protect against competition from health insurers, particularly UnitedHealth Group, that have brought the business of negotiating drugs in-house instead of buying services from a middleman. It will effectively cut out the middleman in negotiating drug prices for health insurers, since CVS is that middleman today, and lock in Aetna's medical members for the pharmacy management side of CVS's business.
The health care space has already undergone considerable consolidation - but it has also faced challenges. Last year, two health insurance mega-mergers between Aetna and Humana and Anthem and Cigna crumbled under antitrust opposition. But a merger between companies that don’t directly compete is thought by many to have a better chance.
"They’re going to be able to offer you a better-functioning insurance package," said Craig Garthwaite, associate professor of strategy at Northwestern's Kellogg School of Management. “There’s some sense in which we’re seeing a reshuffling of the organizational structure, such that insurers are owning providers.”
That fundamental restructuring is part of an industry-wide move away from managing different aspects of patient care - such as drugs or hospitalization - in isolation.
Martin Gaynor, a professor of economics and health policy at Carnegie Mellon University, said that while a CVS-Aetna merger didn’t strike him as a deal that would clearly reduce competition, it wasn't clear why the companies needed to combine at all, since CVS already has Aetna's business as a pharmacy benefit manager.
“A big question mark for me is how does it make the merged company better,” Gaynor said. “I wonder about a lot of these mergers, whether they’re really driven by a true increase in value of the long-term value of the company -- as opposed to seeking a short-term bump in stock prices.”
David Balto, a former policy director at the Federal Trade Commission who led a coalition opposing the insurance mergers, said that he thought the merger would reduce competition and harm consumers.
"For those people who have spent endless hours and long lines at CVS stores, trying to figure out how to meditate while standing, this merger is bad news. It means, increasingly, they’re going to be forced into those long lines. CVS doesn’t win points on service, and its these kind of vertical relationships that raise prices, and deny choices for consumers," Balto said.
Miami Herald staff writer Glenn Garvin contributed to this report.